MPSV4

BIOLOGICAL2 trials

Sponsors

CanSino Biologics Inc.

Conditions

Meningococcal Meningitis

Phase 3

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

Active, not recruitingNCT06226714

CanSino Biologics Inc.Meningococcal Meningitis

Start: 2024-03-01End: 2025-08-31Updated: 2025-07-29

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds

CompletedNCT06700148

CanSino Biologics Inc.Meningococcal Meningitis

Start: 2024-12-14End: 2025-07-16Updated: 2026-08-06